This message contains images. If you don't see images, click here to view.
Advertise in this news brief.




Text Version    RSS    Subscribe    Unsubscribe    Archive    Media Kit           June 04, 2014

Home     About SGO    Education    Membership    Clinical Practice    Public Policy    Blog    Partnerships    Store

 

Pair of pills shows promise for recurrent ovarian cancer
HealthDay News via Philly.com
A combination of two new pills may nearly double the length of survival for patients with recurrent ovarian cancer, according to preliminary clinical trial results. The therapy combines the drugs olaparib and cediranib. It provided nearly 18 months of progression-free survival on average, as opposed to nine months' survival with olaparib treatment alone, said Dr. Joyce Liu, a gynecologic oncologist at Dana-Farber Cancer Institute in Boston.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE  




OVARIAN CANCER


Life-extending ovarian cancer chemotherapy underused, study finds
Health Canal
The use of intraperitoneal (IP) chemotherapy shot up after the National Cancer Institute issued a rare alert in 2006 recommending IP chemotherapy as the new standard of care, said Alexi Wright, M.D., MPH a medical oncologist in the Susan F. Smith Center for Women’s Cancers at Dana-Farber. But after rising from 15 percent in 2005 to 50 percent in 2007, use of IP chemotherapy in eligible ovarian cancer patients did not increase further and may have dropped slightly, she said.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Novel agent bested topotecan in platinum-resistant ovarian cancer
Healio — HemOnc Today
Use of PM01183 resulted in superior efficacy compared with topotecan with regards to ORR, PFS and OS in patients with platinum-resistant ovarian cancer, according to data presented at the ASCO Annual Meeting. “The treatment of patients with platinum-resistant ovarian cancer is a challenge and an unmet medical need,” Andres Poveda, M.D., of the department of medical oncology at the Instituto Valenciano de Oncologia in Spain, said during a presentation here. “These patients require treatment that can overcome resistance.”
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Advertisement
PRODUCT SHOWCASE
  ChemoFx Improves Ovarian Cancer Outcomes
ChemoFx® provides invaluable information to physicians choosing from 20+ equivalent treatment recommendations without prior knowledge of how individual patients may respond. ChemoFx determines platinum resistance in primary ovarian cancer and demonstrates longer overall survival by 14 months in recurrent ovarian cancer, making it instrumental in improving patient outcomes.
 


CERVICAL CANCER


Personalized therapy helped women with advanced cervical cancer
Reuters
A new type of personalized cancer therapy in which immune cells are harvested from patients' tumors, grown in the lab and infused back into patients showed dramatic results in a small, government-led trial in women with advanced cervical cancer, U.S. researchers said on Monday. Two women in the study who had tumors that had spread throughout their bodies had a complete remission of their cancers after a single treatment, according to the study presented at the American College of Clinical Oncology meeting in Chicago.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


HPV-targeting immunotherapy shows early promise in cervical cancer
OncLive
Two patients with metastatic cervical cancer achieved durable complete responses that have so far lasted from 15 to 22 months through an adoptive T-cell therapy (ACT) targeting the human papillomavirus (HPV) in a study that researchers say supports the concept that the experimental immunotherapy approach may be beneficial in a variety of tumor types. Scientists at the National Cancer Institute (NCI) initiated the study to determine whether ACT would be a viable strategy to deploy against epithelial cancers, according to Christian S. Hinrichs, M.D.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


  FEATURED COMPANIES
Exceptional Care, Close to Home

21st Century Oncology – the nation’s largest cancer treatment network and global leader in cancer care – providing integrated clinical teams treating patients collaboratively to improve outcomes.
MORE
Lantheus Proven Success
Discovering, developing and marketing innovative medical imaging agents provides a strong platform from which to bring forward new breakthrough tools for the diagnosis and management of disease. MORE


OBESITY


Few obese patients with gynecologic cancers counseled on weight loss
Oncology Nurse Advisor
Obese patients with gynecologic cancer are rarely counseled on weight loss, even though they expect to be, and report that such discussions would not offend them, according to research presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting. The study “highlights the low degree to which patients report provider involvement in weight management, despite a strong expectation to the contrary,” reported lead author Robert Neff, M.D., at the Ohio State University Wexner Medical Center in Columbus, and coauthors.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


SURVIVORSHIP


Depression and anxiety predict postsurgical pain in women with gynecologic cancer
Oncology Nurse Advisor
Depression and anxiety, not just inflammation, predict pain intensity and interference with daily life among women recovering from gynecologic cancer surgery, according to findings from a longitudinal, prospective study, presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




BREAST CANCER


Study: Drug helps save fertility in breast cancer
MedPage Today
Ovarian failure occurred 70 percent less often in women with hormone receptor-negative breast cancer treated with the hormonal agent goserelin in addition to chemotherapy, a randomized trial showed. Women treated with goserelin had an ovarian failure rate of 8 percent by the most stringent definition, compared with 22 percent among women who did not receive the LHRH agonist in addition to chemotherapy, according to Halle C.P. Moore, M.D., of the Cleveland Clinic, and colleagues. Similar results came from an analysis using a less strict definition of ovarian failure.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE
 



Women's Cancer News
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Jessica Taylor, Senior Medical Editor, 202-684-7169  
Contribute news


Inclusion of advertisements does not constitute SGO endorsement of company products or services.

Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of the Women's Cancer News was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

May 28, 2014
May 21, 2014
May 14, 2014
May 7, 2014






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063